Phase III SELECT-PsA 1 study of Rinvoq shows positive top-line results in psoriatic arthritis.- AbbVie
Related news and insights
UCB has announced positive top-line results from the Phase III BE COMPLETE study which evaluated the efficacy and safety of Bimzelx (bimekizumab) in the treatment of adults with active psoriatic arthritis, who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-?) therapy.
AbbVie has announced that the FDA has approved Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.